3M Sold Off $8 Billion in Healthcare to Pay for Two Chemicals. That's Diversification Eating Itself.

On April 1, 2024, 3M did something a diversified conglomerate is supposed to never have to do: it cut off a healthy arm to pay for two of its own products. It spun out its health-care business as a separate public company called Solventum — $8.2 billion in annual sales, more than 20,000 employees — and loaded that new company with $8.6 billion in debt, partly so it could pay 3M for the privilege of leaving.⁷ The same day, 3M confirmed the resolution of the two lawsuits that made the surgery necessary.⁴ One was about a coating chemistry. The other was about an earplug.

The official story is that 3M is a diversified empire of tens of thousands of products, and diversification means no single failure can sink the ship. That story held for most of a century. It stopped holding when the failures stopped being product failures and started being liability events — and a liability tail does not respect the firewall between business segments.

The lawsuits cost more than the year's profit ever did

Look at the income statement and you would think the business had imploded. In 2023, 3M posted a net loss of roughly $7 billion, against net income of $5.8 billion the year before.¹ But the operating business did not collapse. Net sales were $32.7 billion in 2023, down from $34.2 billion in 2022 and $35.4 billion in 2021 — a soft patch, not a crater.¹ The crater is hiding in one line: selling, general, and administrative expense leapt to $21.5 billion in 2023 from $9.0 billion in 2022.¹ That $12 billion swing is not the cost of running a worse company. It is the cost of settling two of its products.

This is the trap inside the diversification story. A conglomerate spreads operating risk beautifully — if abrasives have a bad year, adhesives carry the quarter. What it does not spread is liability risk, because a legal judgment attaches to the corporate parent, not to a single product line. When one product turns out to have a defect known for years, the courtroom does not care that 59,999 other products were fine. The thesis of diversification is that no one item can hurt the whole. The lesson of 2023 is that a single item, given enough time and enough plaintiffs, can demand the whole company's profit and then some.

The science platform monetized a liability it couldn't see

3M's genius was always its science platform: take a core chemistry and spin it into hundreds of products no competitor would think to make. PFAS — the family of fluorinated compounds behind coatings, stain repellents, and firefighting foams — was exactly that kind of platform chemistry, monetized across category after category. The problem is that the innovation cycle is fast and the liability cycle is slow. A coating reaches the market in a couple of years; the consequences of a 'forever chemical' that never breaks down in the environment surface over decades. By the time the bill arrived, it was enormous: a settlement with public water systems that 3M's own 10-K describes as a commitment of $10.5 billion to $12.5 billion, payable from 2023 all the way out to 2036.³

Worth keeping the numbers honest here. The widely repeated '$12.5 billion' is the nominal ceiling, not the certain payment — the present-value figure is closer to $10.3 billion, and the maximum depends on how many claimants come forward.³⁴ But the precise number is almost beside the point. Whatever it lands at, it is a multiple of any single year's profit, owed by the parent, generated by a chemistry the company spent decades spreading as widely as it possibly could.

The earplug, and the firewall that didn't hold

The second product tells the same story in miniature, and it disposes of the most popular myth about how 3M tried to escape. The Combat Arms earplug — sold to the U.S. military, with a design defect a predecessor manufacturer knew about as early as 2000 — became the largest mass-tort multidistrict litigation in U.S. history, with over 200,000 plaintiffs; the Justice Department had already extracted a $9.1 million False Claims Act settlement back in 2018.⁸ In July 2022, 3M tried the structural move conglomerates reach for when a subsidiary's liability threatens the parent: it put the subsidiary, Aearo Technologies, into Chapter 11, committing $1 billion to a trust and hoping the bankruptcy would wall off the rest.⁶

It did not work. The bankruptcy court refused to extend Aearo's automatic stay to 3M itself, and the case was ultimately dismissed.⁶ The firewall the corporate structure was supposed to provide simply was not there. Thirteen months after the bankruptcy filing, 3M settled directly — $6.0 billion, $5.0 billion in cash and $1.0 billion in its own stock, payable through 2029.⁵ Add that to the PFAS commitment and you are looking at something on the order of $18.5 billion in legal exposure from two product lines, owed by the parent, no subsidiary able to absorb it.

So the company sold the part that still worked

Now the spinoff makes sense. Solventum was not a struggling unit being shed — it was an $8.2 billion business in good health.⁷ And that is exactly why it was useful. 3M retained 19.9% of the shares to monetize within five years, and the new company carried $8.6 billion of debt partly to pay 3M for the transfer.⁷ Strip the language away and the transaction is plain: the conglomerate converted its healthiest diversification into cash and debt capacity at the precise moment it needed to fund the liabilities its other diversification had created. The empire that was supposed to be unbreakable because it was spread so wide was now narrowing itself to survive its own breadth.

Isn't this just bad luck with two products?

The fair objection is that this proves nothing about diversification — it is two unlucky products, decades of legal hindsight applied retroactively, and an operating business that frankly held up fine. And there is real truth there. Organic sales fell only modestly; the headline revenue 'collapse' some data services show is a reclassification artifact from moving health care into discontinued operations, not a real-time loss of customers.²¹ The factories still run. The bankruptcy gambit, not the business, is what failed.

But that defense is precisely the point, not the rebuttal. The whole promise of diversification was that no single bet could threaten the enterprise. If two products out of tens of thousands can force the company to liquidate its best growth business to pay the tab, then the model didn't spread the risk that actually mattered. Operating diversification was never the exposure. The exposure was that a science platform monetized into category after category multiplies not just revenue lines but liability lines — and those don't sit in tidy segments. They all roll up to the same balance sheet. The conglomerate discount investors had quietly priced in for years turned out to be measuring something real.

3M spent a century proving that breadth was strength. Then it spent one filing proving that breadth without a way to contain its own tail is just a larger surface for a lawsuit to attach to. The company that diversified so nothing could sink it ended up selling the part that floated best — to bail out the parts that didn't. That is not diversification failing at the margins. That is diversification eating itself, one settlement at a time.